Liver International

Article	Citations
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	205
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	118
Author's reply: The relationship between systemic inflammation and liver fibrogenesis in patients with cirrhosis	113
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	108
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	88
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	85
Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents	81
High end‐of‐treatment hepatitis B core‐related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy	79
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study	79
Cover Image	74
Reply to: “Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank”	70
Issue Information	66
	63
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	62
A multi‐site, nurse‐coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia	60
	59
Effect of statins on the recurrence of hepatocellular carcinoma after liver transplantation: An illusion revealed by exposure density sampling	59
	57
Tolvaptan for difficult‐ to ‐treat ascites: Difficulties in opening doors for GWAS application	56
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	55
Issue Information	55
Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies	51
Issue Information	51
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?	50
How to get away with liver innate immunity? A viruses’ tale	50

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01	50
MR elastography to predict haemodynamic response to beta‐blockers—The story is still incomplete	50
Natural history, spectrum and outcome of stage 3 AKI in patients with acute‐on‐chronic liver failure	48
Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science	46
	45
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology	45
HBV cure—The light at the end of the tunnel?	45
Hepatitis delta virus infection in the Middle East	42
COVID‐19, adaptative immune response and metabolic‐associated liver disease	41
Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression	41
High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis	41
Vaccination against COVID‐19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis	41
Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma	39
Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon	38
Management of biliary tract cancers in early‐onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort	38
From complement to complosome in non‐alcoholic fatty liver disease: When location matters	37
Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population‐based study	37
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	37
Von Willebrand factor as a predictor of mortality in acute‐on‐chronic liver failure: Do not throw out the baby with the bathwater	37
Response to overcoming the challenges in eliminating viral hepatitis in low‐ and middle‐income countries	37
Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non‐alcoholic fatty liver disease	36
von Willebrand factor does not predict short‐term mortality in ACLF	36
Zonated iron deposition in the periportal zone of the liver is associated with selectively enhanced lipid synthesis	36
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	36
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	36
Issue Information	35
Inside Front Cover	34
Issue Cover	33
	33
Issue Information	33
Liver fibrosis phenotyping and severity scoring by quantitative image analysis of biopsy slides	32
Rare liver diseases are not rare in China	32
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	31
The use of APASL consensus for the diagnosis of hepatitis B virus‐related acute‐on‐chronic liver failure	31
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	30
A new diagnostic criterion for sarcopenia: The fallout of lack of consensus	30
Issue Information	30
Comment on ‘Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure’	30
Different minimal alcohol consumption in male and female individuals with metabolic dysfunction‐associated fatty liver disease	30
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	29
Predicting post‐resection early recurrence of hepatocellular carcinoma: Defining the role of microvascular invasion	29
Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents	29
Is hepatitis delta underestimated?	28
Defining recompensation of alcohol‐related liver disease: A step beyond decompensated cirrhosis	28
Bringing evidence to the MAFLD‐MASLD debate	28
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	28
Extrahepatic autoimmune diseases in autoimmune hepatitis: Effect on mortality	28
COVID‐19 and the liver – Lessons learned	28
Double‐negative T cells regulate the progression of liver fibrosis through Th9 cells differentiation	27
	27

	27
EpCam is required for maintaining the integrity of the biliary epithelium	27
Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C	27
Issue Information	27
Dual‐aetiology MAFLD and metabolic dysfunction	26
Atezolizumab and bevacizumab for HCC in the real world	26
Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD	26
Treatment endpoints for chronic hepatitis D	26
Social work's role in severe depression of MASLD	26
Reply to Yao et al.	26
High histamine levels are associated with acute‐on‐chronic liver failure and liver‐related death in patients with advanced chronic liver disease	24
Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)	24
JAM‐A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence	24
	24
Validation of a novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study	24
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	24
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	24
Assessment of myocardial dysfunction in cirrhotic patients: Should we look at the left atrium rather than at the left ventricle?	23
Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma	23
Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis	23
An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection	23
Response to “Predicting post‐resection early recurrence of hepatocellular carcinoma: Defining the role of microvascular invasion”	23
Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population‐based pre‐exposure prophylaxis program in British Columbia, Canada	23
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	23
Profiles of liver fibrosis evolution during long‐term tenofovir treatment in HIV‐positive patients coinfected with hepatitis B	22
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	22
Think twice about IgG4‐related diseases before operating on hepatic masses	22
The crosstalk network of XIST/miR‐424‐5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer	22
Seroprevalence of hepatitis C virus infection in children: A systematic review and meta‐analysis	22
Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?	22
Liver pathology and biochemistry in patients with mutations in TRIM37 gene (Mulibrey nanism)	22
Confirmation of guideline‐defined hepatitis C screening strategies within the ‘Check‐Up35+’ examination in the primary care setting	22
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	22
Acute‐on‐chronic liver failure: Where do we stand?	22
Abnormal cholesterol metabolism underlies relative adrenal insufficiency in decompensated cirrhosis	21
	21
The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis	21
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	21
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region	21
Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor	21
The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?	21
An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF‐β1 signalling	21
Plasma human neutrophil peptides as biomarkers of disease severity and mortality in patients with decompensated cirrhosis	21
EASL versus LI‐RADS: Intra‐individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC	21
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	21
A novel serum metabolomic panel distinguishes IgG4‐related sclerosing cholangitis from primary sclerosing cholangitis	21
Hypertransaminasemia and liver fibrosis associated with haptoglobin retention and anhaptoglobinemia in a paediatric patient	20
Viral hepatitis C cascade of care: A population‐level comparison of immigrant and long‐term residents	20
Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice	20
A changing landscape of alcohol consumption in the women	20
Rencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuO	20
Hepatocellular adenoma in men: Is it time for a precision approach?	20
Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network	20
DNA Methylation and Target Gene Expression in Fatty Liver Progression From Simple Steatosis to Advanced Fibrosis	20
A Commentary on ‘Safety of Anticoagulation When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis’	19
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors‐based direct‐acting antivirals?	19
Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: A cross‐sectional study in Namibia	19
Correction to Interferons Alpha, Beta, Gamma Each Inhibit HCV Replication at the Level of Internal Ribosome Entry Site‐Mediated Translation	19
Issue Information	19
Measuring the impact of the updated Steatotic liver disease nomenclature and definition	19
Role of liver biopsy in the management of idiosyncratic DILI	19
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	19
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	19
Plastic compounds and liver diseases: Whether bisphenol A is the only culprit	19
Inflammatory myofibroblastoma mimicking cavernous hemangioma in the liver	18
Integrating PNPLA3 into clinical risk prediction	18
Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore	18
Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status	18
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	18
Artificial replication cohort: Leveraging AI‐fabricated data for genetic studies	18
Pathological neutrophil migration predicts adverse outcomes in hospitalized patients with liver cirrhosis	18
Moderation effect of economic status in the association between early life famine exposure and MAFLD in adulthood	18
Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model	18
Serum keratin 19 (CYFRA21‐1) is a prognostic biomarker in severe alcoholic hepatitis	18
An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial	18
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	18
Migration rate using fully covered metal stent in anastomotic strictures after liver transplantation: Results from the BASALT study group	17
Elimination of HDV: Epidemiologic implications and public health perspectives	17
The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis	17
Utility of telemedicine in the treatment of patients with chronic HCV infection using DAAs in remote areas with limited resources	17

Relative adrenal insufficiency in the non‐critically ill patient with cirrhosis: A systematic review and meta‐analysis	17
Autoimmune liver diseases and diabetes: A propensity score matched analysis and a proportional meta‐analysis	17
Is elimination of HCV in 2030 realistic in Central Europe	17
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	17
Update on heme biosynthesis, tissue‐specific regulation, heme transport, relation to iron metabolism and cellular energy	16
Associations between alcohol consumption and hepatic steatosis in the USA	16
Serum‐free light chains as a dependable biomarker for stratifying patients with metabolic dysfunction‐associated steatotic liver disease	16
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip	16
Machine learning in primary biliary cholangitis: A novel approach for risk stratification	16
Long‐term complications in acute porphyria	16
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	16
Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension	16
APASL‐ACLF Research Consortium–Artificial Intelligence (AARC‐AI) model precisely predicts outcomes in acute‐on‐chronic liver failure patients	16
Prognostic implications of CT/MRI LI‐RADS in hepatocellular carcinoma: State of the art and future directions	16
Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells	16
Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients	16
The effect of biliary obstruction, biliary drainage and bile reinfusion on bile acid metabolism and gut microbiota in mice	16
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients	16
Protein O‐GlcNAcylation: The sweet hub in liver metabolic flexibility from a (patho)physiological perspective	15
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	15
Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis	15
Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis	15
Impact of major depression and antidepressant use on alcoholic and non‐alcoholic fatty liver disease: A population‐based study	15
Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection	15
Is elimination of HCV realistic by 2030: France	15
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	15
Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol‐related cirrhosis	15
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	15
Screening for hepatitis C at the time of the pandemic: Need to adjust the shot	15
The relevance of the liver volume increase after ALPPS	15
A history of variceal bleeding is associated with further bleeding under atezolizumab–bevacizumab in patients with HCC	15
Proprotein convertase subtilisin/kexin type 9 regulates the production of acute‐phase reactants from the liver	15
A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017	14
Correction to “Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management”	14
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection	14
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea	14
The MAFLD definition identifies three homogenous groups of patients	14
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	14
Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study	14
Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review	14
Exercise improves surrogate measures of liver histological response in metabolic dysfunction‐associated steatotic liver disease	14
Mycophenolate and SARS‐CoV‐2 vaccination: Mixing oil and water	14
Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease	14
Prognosis algorithms for acute decompensation of cirrhosis and ACLF	14
Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma	14
Authors' response to Guo, Wei et al.	14
Clinical characteristics and prognosis of hospitalized patients with moderate alcohol‐associated hepatitis	14
MYO5B‐associated diseases: Novel liver‐related variants and genotype‐phenotype correlation	14
Issue Information	14
Dual alcohol and metabolic‐related liver disease: Results from a population of liver transplant patients	14
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	13
DRD2‐Mediated AMPK Ubiquitination Regulates the Occurrence of Hepatic Steatosis	13
Inhibition of HSPA8 by rifampicin contributes to ferroptosis via enhancing autophagy	13
Impact of in vitro fertilization‐embryo transfer on mother‐to‐infant transmission in women with chronic HBV infection	13
Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction‐associated steatohepatitis	13
Letter to Editor: ‘Recompensation After TIPS Reduces the Incidence of Hepatocellular Carcinoma and Increases Survival in Patients With Cirrhosis’	13
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48	13
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	13
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	13
Trends in the inpatient burden of alcohol‐related liver disease among women hospitalized in the United States	13
Aurora kinase A regulates liver regeneration through macrophages polarization and Wnt/β‐catenin signalling	13
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	13
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	13
Exosomal ETV4 Derived From M2 Macrophages Induces Growth, Glycolysis and Stemness in Hepatocellular Carcinoma by UpRegulating SULT2B1 Expression	13
In Response to the Letter to the Editor by Walia et al. RE: Kassa et al. 2024 ‘Prevalence, Trends, and Distribution of Hepatitis C Virus Among the General Population in Sub‐Saharan Africa:	13
Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure	13
Hepatic macrophages: Key players in the development and progression of liver fibrosis	13
Novel Emerging Mechanisms in Acetaminophen (APAP) Hepatotoxicity	13
Identification of Clinically Significant Portal Hypertension in cACLD Individuals With Spleen Stiffness Measurement	13
Technical Considerations on Sex Matching in Liver Transplantation for Hepatocellular Carcinoma	13
Genetic Risk Factors for Steatotic Liver Disease After Liver Transplantation	12
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis	12
Safety of Anticoagulation When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis	12
MBOAT7 in liver and extrahepatic diseases	12
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	12
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	12
Global Burden of Major Chronic Liver Diseases in 2021	12
Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors	12
Impact of Direct‐Acting Antiviral Therapy on All‐Cause Mortality in Chronic Hepatitis C Patients	12
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	12
Mechanisms and treatment approaches for ACLF	12
Genetic Variants of GBP4: Reduced Risks for Drug‐Induced Acute Liver Failure in Non‐Finnish European Population	12
Effectiveness and Safety of Glecaprevir/Pibrentasvir in Italian Children and Adolescents With Chronic Hepatitis C: A Real‐Word, Multicenter Study	12
Real‐World Case Supporting Drug‐Induced Autoimmune Hepatitis: Updated Insights and Analysis of the FAERS Data	12
Elevated Porcupine Disrupts Lipid Metabolism and Promotes Inflammatory Response in MASLD	12
Reply: Herbal‐Induced Liver Injury Identification and Prevention	12
Endogenous sex hormones and nonalcoholic fatty liver disease in US adults	12
Liver Injury due to Intravenous Methylprednisolone in the Drug‐Induced Liver Injury Network	12
Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications	11
Sex‐specific effects of PNPLA3 I148M	11
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects	11
Metabolic Dysfunction‐Associated Steatotic Liver Disease Increases the Risk of Severe Infection: A Population‐Based Cohort Study	11
Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice	11
Transplantation of hepatitis D virus patients: Lifelong hepatitis B immunoglobulins?	11
Real‐world epidemiology, treatment patterns and disease burden of patients diagnosed with chronic hepatitis B in Taiwan	11